Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another CAR-T First: Yescarta Wins Lymphoma Funding In England

Executive Summary

Gilead has agreed a confidential deal with NHS England under which its pioneering CAR-T therapy Yescarta will be provided to adult lymphoma patients under the Cancer Drugs Fund. The funding decision gives Yescarta an edge in the lymphoma market over Kymriah, the other EU-authorized CAR-T treatment.
Advertisement

Related Content

CAR-T Funding: It's (Nearly) All About The Price In The UK
Cell And Gene Therapies Test New Waters In Pricing And Reimbursement
Kymriah: England Becomes First In Europe To Say Yes To CAR-T
Gilead And Novartis Unveil EU Marketing Plans For CAR-T Therapies, But Hurdles Remain

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel